Brand Drift | MedicinMan
Brand Drift | MedicinMan
Tuesday, September 1, 2026
28.2
C
Bengaluru
Hot topics
Is Pharma Losing Good SalesPeople
Articles by Gopal Kishore, K. Hariram, Pankaj Mehrotra and Vivek Hattangadi
Covid-19 Impact on Indian Pharma Revenues, Field Force, Doctors – Sunil Attavar, CMD Group Pharma
This is the third and final part of MedicinMan...
Indian Oncology: An Unasked Question, the Challenges Ahead
A Brief History of Scale and an Unasked Question
In...
IPM February 2026: Market Intelligence Report
Executive Summary
The Indian Pharmaceutical Market (IPM) sustained its growth...
Pfizer’s $4.9 Billion Bet: A Game-Changing Move in Obesity Therapeutics
Pfizer’s acquisition of Metsera, announced on September 22, 2025,...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Hot topics
Gila Monster Venom: The Unexpected Spark of the GLP-1 Revolution
In the blistering Sonoran Desert, where temperatures regularly exceed...
The ‘Amazonization’ of Healthcare
Inside this Issue
1. The 'Amazonization' of Healthcare by Salil Kallianpur
Amazon's drive...
The Architects of Immunity: How a Handful of Nations Are Shaping the Future of Global Health
The Paradox of Protection
In the time it takes to...
Hype and Happening: GLP-1 Growth Story – Follow the Patient, not the Primary Sales
Is Obesity (Drugs) Masking Underlying (Metabolic) Risk Factors in...
Why Most AI Healthcare Tools Stall at the Pilot Stage
Artificial intelligence (AI) in healthcare consistently demonstrates remarkable technical...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
How To Power The India Biopharma Regulatory Revolution Now
Beyond the Pharmacy of the World: Why India's Biopharma...
MedicinMan was launched in 2011 as India’s 1st Magazine dedicated to the cause of Field Force Excellence in Pharma and Devices.
Read More
Headlines
Why The Government Must Stop Playing Market Trader And Start Being The Sheriff
India has two very different pharmaceutical regulators living inside...
GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?
STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK...
How To See Dr Reddy’s Nestle In The Wellness Shift
GLP-1 medicines such as semaglutide and tirzepatide are changing...
Newsletter
Get important news delivered directly to your inbox and stay connected!